N/A N=145 The Effect of n-3 Polyunsaturated Fatty Acids in Patients With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change in Heart Rate Variability (HRV) Measure — 13.38; -13.48 ms
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=308 Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.
Arthritis, Psoriatic
Primary: Percentage of Participants Who Achieved a Clinical State of Minimal Disease Activity (MDA-Joints) Response at Week 16 — 16.0; 33.9 percentage of participants — p=0.0008
N/A N=161 Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: RA and if Reasonable for PsA Patients Health Assessment Questionnaire Disability Index HAQ-DI — 1.2; 0.9; 1.1; 0.9 Units on a scale
N/A N=503 AsseSSing Impact in pSoriatic Treatment
Psoriatic Arthritis
Primary: Number of Patients Undergoing Treatment Escalation — 160 Participants
Phase 4 N=63 Subclinical Cardiovascular Disease in Psoriatic Disease
Cardiovascular Diseases · Myocardial Infarction · Atherosclerotic Cardiovascular Disease
Primary: Mean Fold Change in Brachial Vein Endothelial Inflammatory Transcript — 8.6; 2.8 Fold Change
N/A N=368 A Randomized, Open, Parallel, Controlled, Multi-center, Interventional, Cross-sectional Study to Evaluate the Detection Rate of Psoriatic Arthritis in Korean Moderate-to-severe Psoriasis Patients, With or Without Active Screening for Arthritis in Psoriasis (ASAP Study)
Psoriasis
Primary: Detection Rate of Psoriatic Arthritis (PsA) — 8; 6 Participants — p=0.544
N/A N=18 Yoga as Self-Care for Arthritis in Minority Communities
Rheumatoid Arthritis · Arthritis
Primary: Self-Efficacy Exercise — 6.1 units on a scale
Phase 3 N=528 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis (PsA)
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 15.9; 28.0; 30.7 percentage of participants — p=0.0062
Phase 3 N=504 Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 19.0; 30.4; 38.1 percentage of participants — p=0.0001
Phase 2 N=28 Safety and Tolerability of AIN457 in Adults (18-65 Years) With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Number of Participants With Adverse Events and Serious Adverse Events — 5; 2; 0; 0 Participants
Phase 3 N=488 PALACE 2: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.9; 37.4; 32.1 percentage of participants — p=0.0060
Phase 3 N=44 Efficacy of Golimumab in Combination With Methotrexate (MTX) Versus MTX Monotherapy, in Improving Dactylitis, in MTX naïve Psoriatic Arthritis Patients
Psoriatic Arthritis
Primary: Dactylitis Severity Score (DSS) — -2; -5 change of score on a scale — p==0.026
N/A N=141 A Study to Learn About the Study Medicine (Called Tofacitinib) in People With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Change From Baseline to 6 Months in Tender Joint Count (68) — -2.5; -3.2; -2.0 Tender joints
Phase 3 N=505 PALACE 3: Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16 — 18.3; 28.4; 40.7 percentage of participants — p=<0.0001
Phase 3 N=484 Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Psoriatic Arthritis
Primary: ACR20 (American College of Rheumatology 20% Improvement) Response Rate Through Week 16 — 41.8; 48.9; 24.7 Percentage of Participants